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SUMMARY. HIV/hepatitis C virus (HCV) co-infection places a
growing burden on the HIV/AIDS care delivery system.
Evidence-based estimates of health services utilization among
HIV/HCV co-infected patients can inform efficient planning.
We analyzed data from the ACTG Longitudinal Linked
Randomized Trials (ALLRT) cohort to estimate resource
utilization and disability among HIV/HCV co-infected
patients and compare them to rates seen in HIV mono-
infected patients. The analysis included HIV-infected subjects
enrolled in the ALLRT cohort between 2000 and 2007 who
had at least one CD4 count measured and completed at least
one resource utilization data collection form (N = 3143).
Primary outcomes included the relative risk of hospital
nights, emergency department (ED) visits, and disability days
for HIV/HCV co-infected vs HIV mono-infected subjects.
When controlling for age, sex, race, history of AIDS-defining
events, current CD4 count and current HIV RNA, the rela-
tive risk of hospitalization, ED visits, and disability days for
subjects with HIV/HCV co-infection compared to those with
HIV mono-infection were 1.8 (95% CI: 1.3–2.5), 1.7 (95%
CI: 1.4–2.1), and 1.6 (95% CI: 1.3–1.9) respectively. Pro-
grams serving HIV/HCV co-infected patients can expect
approximately 70% higher rates of utilization than expected
from a similar cohort of HIV mono-infected patients.
Keywords: health services research, hepatitis C/economics,
HIV infections/economics, outcomes research, resource
allocation.
INTRODUCTION
Approximately 15–30% of HIV-infected patients in the
United States are co-infected with hepatitis C virus (HCV)
[1]. Compared to patients with HCV mono-infection, HIV/
HCV co-infected patients have higher rates of progression
of liver disease [2,3] and greater medication-related
hepatotoxicity [4]. Treating HCV co-infection in HIV-in-
fected patients is difficult [5–7], but because individuals
with HIV/HCV co-infection have higher rates of mor-
bidity and mortality than HIV mono-infected patients
[8–10], the potential benefits of HCV therapy are large
[11].
As survival with HIV infection has improved, liver-related
mortality has become an increasingly important cause of
death among HIV-infected patients, and HIV/HCV co-infec-
tion has placed an increasing burden on the health care
delivery system [12–14].
Because many patients with HIV/HCV co-infection have
poor access to care and rely on government programs such
as Medicaid and state AIDS Drug Assistance Programs
Abbreviations: ALLRT, ACTG Longitudinal Linked Randomized
Trial; ED, emergency department; HCV, Hepatitis C Virus; IQR,
interquartile range.
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(ADAPs) [15], co-infection represents a particular challenge
to policy makers seeking to provide adequate care to HIV-
infected patients while operating within budget constraints.
Accurate estimates of resource utilization attributable to
HIV/HCV co-infection are needed to inform resource allo-
cation [16].
We used data from HIV-infected subjects in the
ACTG Longitudinal Linked Randomized Trials (ALLRT)
cohort to assess and compare health care utilization and
disability among HIV/HCV co-infected and HIV mono-
infected patients [17].
METHODS
Data
ACTG Longitudinal Linked Randomized Trials is a multi-
centre, prospective cohort study of HIV-infected subjects
who were antiretroviral treatment naı¨ve or experienced
and enrolled into selected ACTG trials that provided ran-
domized antiretroviral treatment regimens or strategies
[17]. All subjects provided written informed consent. ALL-
RT enrolment began in 2000 and has since been ongoing.
At baseline, subjects report demographic information,
including history of injection drug use and history of AIDS-
defining events (ADEs). Laboratory analyses at study entry
include CD4 count and HIV RNA. HCV antibody testing
was used to identify HCV co-infection, though its timing
evolved over the 2000–2007 study period. HCV AB testing
at ALLRT entry was introduced in the year 2002. Subjects
who enrolled prior to 2002 had HCV AB testing at their
next ALLRT visit. In 2006, HCV AB testing expanded to
include repeat testing every 96 weeks. Subjects who ever
had a positive HCV AB were considered HCV infected for
the analysis.
ACTG Longitudinal Linked Randomized Trials study visits
are at 16-week intervals. At each study visit, subjects
provide an interval history of ADEs, as well as samples for
laboratory analyses including CD4 count and HIV RNA.
Subjects also complete an annual study form asking them
to recall the preceding 4 months and to report: (i) the
number of nights they stayed in a hospital (hospital
nights), (ii) the number of visits they made to an emer-
gency department (ED visits), (iii) the number of days they
spent in bed, and (iv) the number of days they felt forced to
reduce their usual daily activities owing to illness. We
analysed data from the ALLRT cohort to compare self-
reported rates of: (i) hospital nights, (ii) ED visits, and (iii)
disability days in patients with HIV/HCV co-infection and
HIV mono-infection. The analysis included ALLRT subjects
who enrolled between 2000 and 2007 with known HCV
status who provided at least one CD4 count and completed
at least one study form reporting health care utilization
(N = 3143). Data for the analysis were collected on sub-
jects through June 30, 2007.
Primary outcomes
Incidence of hospital nights and incidence of emergency
department visits
Responses were provided as count data (0, 1–2, 3–5, 6–10,
11–16, >16 nights or visits). For responses of >16 nights or
visits, subjects provided free text entry of the exact number of
nights/visits in the prior 4 months. To provide a conservative
estimate, and because some intervals did not have an integer
mid-point, we used the lower limit of the interval to estimate
the number of nights spent in the hospital and the number of
ED visits in the preceding 4 months. For responses >16, we
used the exact number of nights or visits provided in the free
text answer field. Each completed study form represented
4 months of contributed follow-up time. We report observed
and adjusted rates in terms of the number of hospital nights
and the number of ED visits per 100 person-years with each
study form contributing 4 months of follow-up time.
Incidence of disability day
Subjects responded to two questions soliciting information
about their level of disability: (i) During the past 4 months,
how many days did you cut down on your usual daily
activities, such as your job, housework, or school?; and (ii)
During the past 4 months, how many days did you stay in
bed because you were not feeling well? Both questions were
adapted with a longer recall period (4 months vs 4 weeks)
from previously validated measures of health-related quality
of life including the 38-item HIV-adapted Medical Outcomes
Study measure and the HIV Cost and Services Utilization
Study (HCSUS) measure [18–21]. We performed analyses on
each outcome separately. To provide a single measure of
disability defined as days spent either in bed or with reduced
daily activities, we combined responses from the two ques-
tions to obtain a single measure of disability days. Because
the number of days spent in bed should be a subset con-
tained entirely within the number of days forced to cut back
on usual daily activities, we used the larger number from the
two responses as the estimate of the number of disability
days in the preceding 4 months. We also report this rate per
100 person-years.
Current CD4 count and HIV RNA
To calculate CD4-stratum-specific rates, we treated CD4
count as a time-varying covariate such that subjects could
contribute time to multiple CD4 count strata (£100/lL,
101–200/lL, 201–350/lL, and >350/lL). Each completed
study form contributed 4 months of follow-up time to the
CD4 stratum corresponding to the CD4 count at the mid-
point of the 4-month interval. We used linear interpolation
between the CD4 count when the subject completed the
study form and the prior 16-week CD4 count to estimate the
CD4 count at the mid-point of the 4-month interval. Current
HIV RNA was taken from the same time point as the
measurement of resource utilization.
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Analyses
We first calculated observed rates of hospital nights, ED
visits, and disability days for HIV mono-infected and HIV/
HCV co-infected subjects stratified by current CD4 count. We
next constructed Poisson regression models of each outcome
with HCV serostatus as the predictor of interest, using
backward elimination to construct the most parsimonious
model. Candidate covariates included age, sex, race, history
of injection drug use (ever vs never), history of ADE, current
CD4 count (£100/lL, 101–200/lL, 201–350/lL, vs >350/
lL), current HIV RNA (£400 vs >400 copies/mL), and year
in which the data were collected (2-year intervals). Covari-
ates significant at the P < 0.05 threshold were included in
the final model. We also constructed models that included
the cross product of CD4 stratum and HCV serostatus to test
for possible effect modification of the impact of HCV
co-infection on different CD4 counts.
We report the relative risk of each outcome for patients
with HIV/HCV co-infection vs HIV mono-infection. We
also used the final model to estimate adjusted, CD4-
stratum-specific incidences of hospital nights, ED visits, and
disability days.
RESULTS
The analysis included 3143 subjects of whom 372 (11.8%)
had HIV/HCV co-infection (Table 1). Overall, 83% of the
cohort were men and 50% of subjects were non-white. The
median baseline CD4 count was 244/lL [interquartile range
(IQR) 104–408], and median HIV RNA was 4.6 log10 cop-
ies/mL (IQR 3.9–5.3 log10 copies); these were similar among
HIV/HCV co-infected and HIV mono-infected subjects. Sub-
jects with HIV/HCV co-infection were somewhat older and
more frequently non-white than HIV mono-infected subjects
(Table 1).
In subjects with HIV/HCV co-infection, observed follow-up
time ranged from 92 person-years in the CD4 £100/lL
stratum to 332 person-years in the CD4 >350/lL stratum.
In subjects with HIV mono-infection, follow-up time ranged
from 868 person-years in the CD4 £100/lL stratum to 2602
person-years in the CD4 >350/lL stratum (Table 2).
In every CD4 stratum, observed incidences of hospital-
ization, ED visits, and disability days were higher in HIV/
HCV co-infected patients than in HIV mono-infected pa-
tients, with larger differences seen in subjects with CD4
£350/lL vs CD4 >350/lL (Table 2).
In adjusted analyses, HCV serostatus, as well as age, sex,
history of ADE, current CD4 count, and current HIV RNA
were all significantly associated with resource utilization
(Table 3). Reporting a history of injection drug use was not
associated with higher resource utilization or disability. In
the final model, controlling for age, sex, race, history of ADE,
current CD4 count, and current HIV RNA, HIV–HCV
co-infection was associated with significantly higher rates of
hospital nights, ED visits, and disability days. Relative rates
were the following: 1.8 (95% CI 1.3–2.5) for hospital nights,
1.7 (95% CI 1.4–2.1) for ED visits, and 1.6 (95% CI 1.3–1.9)
for disability days (Table 3). When we analysed separately
the incidence of days spent in bed and days spent with
reduced daily activities, HIV–HCV co-infection remained
significantly associated with each outcome. Relative rates
were 1.2 (95% CI 1.1–1.4) for days spent in bed, and 1.3
(95% CI 1.1–1.4) for days with reduced daily activities. Tests
for an interaction between HCV serostatus and current CD4
count revealed no clinically relevant effect size and were not
statistically significant.
Choosing men, non-white, 40-year-old HIV/HCV
co-infected subjects with HIV RNA <400 copies/mL and no
history of ADEs as a representative group of HIV/HCV
co-infected patients, adjusted CD4-stratum-specific rates of
hospital nights ranged from 294/100 person-years with CD4
Table 1 Baseline characteristics
Characteristic
Cohort overall
(n = 3143)
HIV/HCV Co-infected
(n = 372)
HIV mono-infected
(n = 2771)
Age, mean (SD), years 40 (9.2) 43 (7.7) 40 (9.3)
Male, no. (%) 2619 (83) 293 (79) 2326 (84)
Race no. (%)
White 1579 (50) 137 (37) 1442 (52)
African-American 875 (28) 155 (42) 720 (26)
Hispanic 603 (19) 70 (19) 533 (19)
Other 86 (3) 10 (3) 76 (3)
CD4 count, median/lL (IQR) 244 (104–408) 251 (115–427) 244 (100–405)
HIV RNA, log10 median copies/mL (IQR) 4.6 (3.9–5.3) 4.6 (3.6–5.1) 4.6 (3.9–5.3)
History of ADE, no. (%) 669 (21) 72 (19) 597 (22)
History of injection drug use, no. (%) 304 (9.7) 191 (51%) 113 (4)
ALLRT, ACTG Longitudinal Linked Randomized Trials; HCV, hepatitis C virus; SD, standard deviation; IQR, interquartile range;
ADE, AIDS-defining event.
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£100/lL to 57/100 person-years with CD4 >350/lL
(Fig. 1). Adjusted incidence of ED visits for patients with
HIV/HCV co-infection was 166, 100, 77, and 69/100 per-
son-years for patients with CD4 counts £100/lL, 101–200/
lL, 201–350/lL, and >350/lL, respectively. Adjusted
incidence of disability days for patients with HIV/HCV
co-infection was 1350, 669, 596, and 466/100 person-
years for patients with CD4 counts £100/lL, 101–200/lL,
201–350/lL, and >350/lL, respectively.
DISCUSSION
As patients live longer with HIV infection and AIDS-related
complicationsdecline, co-morbidities suchasHCVco-infection
play a larger role in determining long-term outcomes and
place a substantial demand on the health care delivery
system [12–14,22]. This analysis provides evidence that in
a cohort of HIV-infected patients in the United States,
co-infection with HCV is associated with greater resource
utilization, independent of the effect of HCV co-infection on
CD4 count or HIV RNA.
In every CD4 stratum, observed incidence of hospital
nights, ED visits, and disability days was higher in HIV/HCV
co-infected patients than in HIV mono-infected patients. In
the light of high absolute rates of resource utilization, espe-
cially at lower CD4 counts, HIV/HCV co-infection likely
results in a substantial burden on health care delivery
resources. For example, in a setting where 20% of HIV-
infected patients have HIV/HCV co-infection, a program
serving 10 000 men, non-white, HIV-infected patients with
suppressed viral load and CD4 counts between 200 and
350/lL could expect approximately 700 additional hospital
nights per year than would be expected from a similar cohort
with only HIV mono-infection.
These findings are important for policy makers and pro-
gram administrators planning budgets for HIV care in the
current environment of resource constraints. While past
research has investigated the relative increase in mortality
Table 2 Follow-up time observed and unadjusted incidence rates of hospital nights, ED visits, and disability days in the ALLRT
cohort
Current CD4
Person-
years
observed
Hospital nights/100 PY
(95% CI)
ED visits/100 PY
(95% CI)
Disability days/100 PY
(95% CI)
HIV/
HCV HIV HIV/HCV HIV HIV/HCV HIV HIV/HCV HIV
£100/lL 92 868 170 (143–197) 90 (84–96) 32 (20–43) 28 (24–32) 832 (773–891) 425 (295–555)
101–200/lL 141 873 70 (56–83) 33 (29–37) 25 (17–33) 13 (11–16) 289 (261–317) 218 (158–279)
201–350/lL 178 1616 34 (25–42) 12 (10–14) 28 (20–36) 8.6 (7.2–10) 189 (169–210) 155 (100–210)
>350/lL 332 2602 8.7 (5.6–12) 7.6 (6.5–8.7) 11 (7.6–15) 6.1 (5.2–7.1) 161 (147–175) 134 (99–169)
ALLRT, ACTG Longitudinal Linked Randomized Trials; PY, person-years; ED, emergency department; 95% CI, 95% confidence
interval; HIV/HCV, HIV/hepatitis C virus co-infected.
Table 3 Adjusted relative risk of resource utilization and disability days in HIV/HCV co-infected vs HIV mono-infected subjects
Variable
Hospital nights ED visits Disability days
RR 95% CI RR 95% CI RR 95% CI
HCV serostatus 1.8 1.3–2.5 1.7 1.4–2.1 1.6 1.3–1.9
Age (per 10 years) 1.1 1.0–1.3 1.0 0.9–1.1 1.2 1.1–1.3
Female 1.5 1.1–2.1 1.3 1.1–1.6 1.1 0.9–1.4
White race 0.9 0.7–1.1 0.9 0.8–1.1 1.8 1.5–2.1
History of ADE* 2.9 1.9–4.3 1.7 1.3–2.4 1.6 1.2–2.2
Current HIV RNA <400 copies/mL* 0.4 0.4–0.6 0.5 0.5–0.6 0.7 0.6–0.8
Current CD4 (vs CD4 >350/lL)*
£100/lL 5.2 3.7–7.3 2.4 1.9–3.0 2.9 2.4–3.6
101–200/lL 2.3 1.7–3.0 1.4 1.2–1.8 1.4 1.2–1.7
201–350/lL 1.4 1.0–2.0 1.1 1.0–1.3 1.3 1.1–1.5
HCV, hepatitis C virus; ED, emergency department; RR, relative risk; 95% CI, 95% confidence interval; ADE, AIDS-defining
event; *treated as a time-updated covariate.
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attributable to HCV co-infection, it has not translated find-
ings into estimates of resource utilization [8–10,23–25].
Knowledge of the impact of HCV co-infection on resource
consumption makes realistic projections possible, thereby
avoiding unanticipated shortfalls and financial crises. Fur-
ther, although treating HCV co-infection in HIV-infected
patients is difficult [5–7], understanding increased resource
utilization associated with HCV co-infection informs the
potential economic benefits of its treatment. Such fully
informed projections are particularly important for Medicaid
and for Health Resources Services Administration (HRSA)–
funded programs, such as ADAPs and local health programs,
which play a central role in providing health services for
HIV/HCV co-infected patients in the United States
[16,26,27]. Overall, we find that programs serving HIV/HCV
co-infected patients can expect 1.6–1.8 times higher rates of
hospital nights, ED visits, and disability days in the HIV/HCV
co-infected patients than in a similar group of HIV mono-
infected patients.
There are several limitations to this study. First, the data
set does not include HCV RNA levels. For the purpose of
analysis, we assume that patients with positive HCV anti-
body have chronic HCV infection. Data indicate, however,
that approximately 30% of those with HCV antibodies have
negative HCV RNA, indicating that they have cleared their
HCV infection [23,28,29]. To the extent that we misclassi-
fied some patients with positive HCV antibody and negative
HCV RNA as chronically HCV infected, however, we likely
underestimated the true effect of HCV co-infection on
resource utilization. Reported findings, therefore, represent a
conservative estimate.
Second, as with any non-randomized study design, the
reported findings may reflect residual confounding by an
unmeasured patient characteristic that correlates both with
the likelihood of HCV co-infection and resource utilization
rates. The possibility that HCV co-infection is a proxy
marker for a more risky lifestyle is raised by data from the
Strategies for Management of Anti-Retroviral Therapy
(SMART) study, suggesting that most excess mortality seen
in HIV/HCV co-infected patients is because of non-liver,
non-ADE-related causes [9]. While we cannot exclude
residual confounding in the results, this analysis did eval-
uate the effect of a history of injection drug use, but it was
not additionally associated with resource utilization in
models that included HCV status. To the extent that HCV
co-infection is a marker for excess risk, much of that risk is
likely correlated with having a history of injection drug use
[9]. Most importantly, the biologic mechanism by which
HIV/HCV co-infection increases resource utilization is
beyond the scope of this study. More relevant from a policy
and planning perspective is the finding that a cohort of
patients with HIV/HCV co-infection will have substantially
elevated rates of resource utilization compared to a similar
cohort of HIV mono-infected patients. Parameters
commonly employed to project resource utilization, such as
CD4 count and history of ADEs, do not accurately capture
expected resource consumption from patients with HIV/
HCV co-infection [30].
Third, the generalizability of these findings may be limited
because the cohort is comprised entirely of subjects who
enrolled in ACTG clinical trials. While subjects come from
diverse backgrounds (50% non-white and 17% women),
their resource utilization patterns may differ from those on
the parent ACTG studies who did not enter the ALLRT
cohort, or from patients who are not in a research study
setting. Patients enrolled in ALLRT, however, are not
enrolled in clinical trials throughout the course of their
follow-up [17]. While all subjects began the study as part of
a randomized ACTG clinical trial, many remained enrolled
only in ALLRT when their parent study closed and were thus
enrolled in an observational study for the majority of their
follow-up time.
Fig. 1 Adjusted CD4-stratum-specific
incidence of hospital nights for male,
non white patients aged 40 years with
HIV/HCV co-infection, HIV RNA < 400
copies/mL, and no history of AIDS
defining events compared to similar
patients with HIV mono-infection.
Error bars represent 95% confidence
intervals.
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In the current environment of increasing resource con-
straints for public programs, efficient planning becomes
increasingly important [31]. HIV/HCV co-infection is a
growing cause of morbidity and mortality among
HIV-infected patients in the United States and places a
disproportionate burden on public programs that often face
difficult resource allocation decisions. Policy makers can use
these results to project the impact that HIV/HCV co-infection
will have on their budgets and make appropriate funding
adjustments. By doing so, they can take an important step
towards ensuring uninterrupted, high-quality medical
services for both HIV mono-infected and HIV/HCV
co-infected patients.
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